Riding high on the success of the festival season, Hero MotoCorp has reduced its after-festival channel inventory to its lowest level in over three years
In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India
The sale was executed by Cipla (EU) Limited, UK, and Meditab Holdings Limited, Mauritius, both wholly-owned subsidiaries of Cipla Limited
On a sequential basis, the company exhibited a 3.15 per cent increase in revenue along with EBITDA, which grew 21 per cent year-on-year
The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe
This approval follows the green light granted by the European Commission (EC) for marketing authorisation in the European Union (EU) back in September
Prevalence of diabetes no longer confined to just older demographics, Vitamin B12 deficiency may be a cause
The Generics segment, encompassing APIs and Generic Formulations, exhibited a 4 per cent year-on-year growth, reaching Rs 676 crore
Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD
Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders
On a sequential basis, the company exhibited an 8.29 per cent increase in revenue, along with a PAT which rose 30.17 per cent
The newly introduced Rocuronium Bromide Injection is available in two formulations
The generics business contributed 9.95 per cent of Cipla's turnover and 0.92 per cent of its net worth in the financial year ended March 31, 2023
On a sequential basis, the company exhibited a 16.26 per cent increase in revenue
The API business reported a 10 percent growth in revenues, reaching Rs 322 crores in the quarter
EBITDA stood at Rs 77.8 crore, declining 6.2 per cent year-on-year and growing 16.1 per cent sequentially
According to industry experts, the egg-freezing market in India is still in its early stages but is poised for growth in the coming years
Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE
On a sequential basis, the company exhibited a 4.83 per cent increase in revenue and the PAT increased by 57.35 per cent, respectively
The report highlights that the electric twowheeler (e2W) segment has emerged as a frontrunner, accounting for 85-90 per cent of total EV sales in FY23